Shelton Wealth Management LLC Purchases Shares of 28,000 Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Shelton Wealth Management LLC purchased a new stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 28,000 shares of the biopharmaceutical company’s stock, valued at approximately $29,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Meritage Portfolio Management lifted its position in shares of Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 6,740 shares in the last quarter. XTX Topco Ltd raised its position in shares of Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 64,981 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Sangamo Therapeutics by 55.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 38,850 shares during the last quarter. Virtu Financial LLC acquired a new position in Sangamo Therapeutics in the third quarter valued at about $150,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Sangamo Therapeutics during the 2nd quarter worth approximately $67,000. 56.93% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on SGMO. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a report on Thursday, January 2nd. Barclays increased their price target on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Truist Financial upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Friday, December 13th. Wells Fargo & Company dropped their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a report on Tuesday, December 31st. Finally, Jefferies Financial Group decreased their price objective on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, December 31st. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $5.50.

Sangamo Therapeutics Price Performance

Shares of NASDAQ SGMO opened at $1.09 on Friday. The company has a market capitalization of $227.43 million, a price-to-earnings ratio of -1.45 and a beta of 1.29. Sangamo Therapeutics, Inc. has a 1-year low of $0.30 and a 1-year high of $3.18. The business has a 50-day moving average of $1.93 and a 200-day moving average of $1.28.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $49.41 million during the quarter, compared to analyst estimates of $26.55 million. During the same quarter last year, the firm earned ($0.34) EPS. Research analysts expect that Sangamo Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.